Capital Advisors Inc. OK Takes Position in OPKO Health, Inc. (NASDAQ:OPK)

Capital Advisors Inc. OK bought a new stake in OPKO Health, Inc. (NASDAQ:OPK) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 150,000 shares of the biotechnology company’s stock, valued at approximately $220,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in OPK. Rubric Capital Management LP boosted its holdings in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares in the last quarter. PFG Investments LLC grew its position in OPKO Health by 9.4% in the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock valued at $1,707,000 after purchasing an additional 99,795 shares during the period. Clearline Capital LP bought a new stake in OPKO Health during the 3rd quarter valued at $1,083,000. Finally, Barclays PLC raised its holdings in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of analyst reports. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.64 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a 50-day moving average of $1.53 and a 200-day moving average of $1.53. OPKO Health, Inc. has a one year low of $0.86 and a one year high of $1.76. The company has a market cap of $1.12 billion, a P/E ratio of -8.63 and a beta of 1.63.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the purchase, the chief executive officer now directly owns 212,411,477 shares of the company’s stock, valued at $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders bought 1,621,609 shares of company stock worth $2,472,710. Insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.